InterCure

Historical price data

InterCure's mission is to improve patients' quality of life through the development and global distribution of high-quality, pharmaceutical-grade cannabis products. Its key achievement is establishing a leading, vertically integrated position in Israel's medical cannabis market through its GMP-certified subsidiary, Canndoc. The company's strategy focuses on leveraging its clinical data, regulatory expertise, and production standards to expand into international markets and build a robust evidence-based medical franchise.

A vertically integrated pharmaceutical-grade platform combining proprietary cannabis genetics, advanced controlled-environment cultivation, and full GMP-certified manufacturing for extraction, formulation, and packaging of standardized cannabis-based medicines.

InterCure competes with large Canadian producers (e.g., Canopy Growth, Tilray) on scale, pharmaceutical companies (e.g., Jazz/GW Pharma) on science, and local producers on cost. Its core competitive advantages are its vertically integrated GMP platform in Israel and its focus on pharmaceutical-grade standards and clinical data.